Markets:

Overview

News

Currencies

International

Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

24.23 +0.63 (+2.67%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Zymeworks Inc. - Common Stock

< Previous 1 2 3 4 Next >

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

The market is filled with gapping stocks in Monday's session. ↗

November 17, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Mixed Signals Point to Cautious Open for U.S. Markets as Tech Shines Amidst Economic Data Delays

November 17, 2025

U.S. equity futures are signaling a mixed but largely cautious start to the trading day on November 17, 2025, with technology stocks once again taking the lead, while broader indices like the Dow Jones...

Via MarketMinute

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer ↗

November 17, 2025

Shares of Jazz Pharmaceuticals and Zymeworks catapulted Monday on positive test results for a gastric cancer drug.

Via Investor's Business Daily

These stocks are moving in today's pre-market session ↗

November 17, 2025

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 17, 2025

Via Benzinga

Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 17, 2025

From Zymeworks Inc.

Via GlobeNewswire

5 Analysts Have This To Say About Zymeworks ↗

October 24, 2025

Via Benzinga

Zymeworks Inc (NASDAQ:ZYME) Shows Strong Technical and Fundamental Momentum ↗

November 11, 2025

Discover how Zymeworks (ZYME) combines strong technical trends with accelerating earnings and sales growth, making it a top high-growth stock candidate.

Via Chartmill

Zymeworks Inc (NASDAQ:ZYME) Reports Mixed Q3 2025 Results with Narrower Loss but Revenue Miss ↗

November 06, 2025

Zymeworks Q3 2025: Narrower-than-expected loss and strong cash position, though revenue missed estimates. Clinical pipeline advances with promising data.

Via Chartmill

Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 06, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Announces Participation in Upcoming Investor Conferences

October 28, 2025

From Zymeworks Inc.

Via GlobeNewswire

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺ at AACR-NCI-EORTC Conference

October 23, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

October 16, 2025

From Zymeworks Inc.

Via GlobeNewswire

Broadcom To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 14, 2025

Via Benzinga

This RPM International Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

October 14, 2025

Via Benzinga

Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International Conference

October 13, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer

October 09, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit ↗

September 02, 2025

Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251.

Via Benzinga

Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update ↗

September 02, 2025

The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer.

Via Stocktwits

Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager

September 02, 2025

From Zymeworks Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 22, 2025

Via Benzinga

Which stocks are moving after the closing bell on Friday? ↗

August 22, 2025

Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.

Via Chartmill

Zymeworks Announces Participation in Upcoming Investor Conferences

August 19, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry

August 11, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 07, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate

July 28, 2025

From Zymeworks Inc.

Via GlobeNewswire

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

July 17, 2025

Company to participate in investor conferences in July and August

From Zymeworks Inc.

Via GlobeNewswire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.